Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer

被引:123
作者
Zhou, Yufei [1 ]
Li, Shaoxia [2 ]
Li, Jiangtao [3 ]
Wan, Dongfeng [1 ]
Li, Quanxing [1 ]
机构
[1] Peoples Hosp Dongying, Dept Thorac Surg, 317 Nanyi Rd, Dongying 257091, Peoples R China
[2] Peoples Hosp Dongying, Dept Pediat, Dongying, Peoples R China
[3] Second Peoples Hosp Laiyang, Dept Gen Surg, Yantai, Peoples R China
关键词
microRNA-135a; Insulin-like growth factor-1; IGF-1/PI3K/Akt signaling pathway; Non-small cell lung cancer; Proliferation; Migration; Invasion; Angiogenesis; GROWTH-FACTOR; 1; EXPRESSION; SURVIVAL; SUPPRESSOR; RECEPTOR; ROCK1; NSCLC;
D O I
10.1159/000479207
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective: This study explored the ability of microRNA-135a (miR-135a) to influence cell proliferation, migration, invasion, apoptosis and tumor angiogenesis through the IGF-1/PI3K/Akt signaling pathway in non-small cell lung cancer (NSCLC). Methods: NSCLC tissues and adjacent normal tissues were collected from 138 NSCLC patients. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression levels of miR-135a and IGF-1, PI3K, Akt, VEGF, bFGF and IL-8 mRNA; western blotting was used to determine the expression levels of IGF-1, PI3K and Akt protein; and enzyme-linked immunosorbent assay (ELISA) was used to analyze the expression levels of VEGF, bFGF and IL-8 protein. Human NSCLC cell lines (A549, H460, and H1299) and the human bronchial epithelial cell line (HBE) were selected. A549 cells were assigned to blank, negative control (NC), miR-135a mimics, miR-135a inhibitors, IGF-1 siRNA and miR-135a inhibitors + IGF-1 siRNA groups. The following were performed: an MTT assay to assess cell proliferation, a scratch test to detect cell migration, a Transwell assay to measure cell invasion, and a flow cytometry to analyze cell apoptosis. Results: The expression level of miR-135a was lower while those of IGF-1, PI3K and Akt mRNA were higher in NSCLC tissues than in the adjacent normal tissues. Dual-luciferase reporter assay indicated IGF-1 as a target of miR-135a. The in vitro results showed that compared with the blank group, cell proliferation, migration and invasion were suppressed, mRNA and protein levels of IGF-1, PI3K, Akt, VEGF, bFGF and IL-8 were reduced, and cell apoptosis was enhanced in the miR-135a mimics and IGF-1 siRNA groups. Compared with the IGF-1 siRNA group, cells in the miR-135a inhibitors + IGF-1 siRNA group demonstrated increased cell proliferation, migration and invasion, elevated mRNA and protein levels of IGF-1, PI3K, Akt, VEGF, bFGF and IL-8 and reduced cell apoptosis. Conclusion: These findings indicated that miR-135a promotes cell apoptosis and inhibits cell proliferation, migration, invasion and tumor angiogenesis by targeting IGF-1 gene through the IGF-1/PI3K/Akt signaling pathway in NSCLC. (C) 2017 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:1431 / 1446
页数:16
相关论文
共 42 条
[11]   IGF-1 Mediates PTEN Suppression and Enhances Cell Invasion and Proliferation via Activation of the IGF-1/PI3K/Akt Signaling Pathway in Pancreatic Cancer Cells [J].
Ma, Jiachi ;
Sawai, Hirozumi ;
Matsuo, Yoichi ;
Ochi, Nobuo ;
Yasuda, Akira ;
Takahashi, Hiroki ;
Wakasugi, Takehiro ;
Funahashi, Hitoshi ;
Sato, Mikinori ;
Takeyama, Hiromitsu .
JOURNAL OF SURGICAL RESEARCH, 2010, 160 (01) :90-101
[12]   PTEN regulate angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells [J].
Ma, Jiachi ;
Sawai, Hirozumi ;
Ochi, Nobuo ;
Matsuo, Yoichi ;
Xu, Donghui ;
Yasuda, Akira ;
Takahashi, Hiroki ;
Wakasugi, Takehiro ;
Takeyama, Hiromitsu .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2009, 331 (1-2) :161-171
[13]   Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients [J].
Ma, Ying ;
Ma, Lin ;
Guo, Quan ;
Zhang, Shulan .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2010, 29
[14]   Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer [J].
Masago, Katsuhiro ;
Fujita, Shiro ;
Togashi, Yosuke ;
Kim, Young Hak ;
Hatachi, Yukimasa ;
Fukuhara, Akiko ;
Nagai, Hiroki ;
Irisa, Kaoru ;
Sakamori, Yuichi ;
Mio, Tadashi ;
Mishima, Michiaki .
ONCOLOGY REPORTS, 2011, 26 (04) :795-803
[15]   Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer A National Cancer Database Survey [J].
Morgensztern, Daniel ;
Ng, Shean Huey ;
Gao, Feng ;
Govindan, Ramaswamy .
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (01) :29-33
[16]   Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma [J].
Navarro, Alfons ;
Diaz, Tania ;
Martinez, Antonio ;
Gaya, Anna ;
Pons, Aina ;
Gel, Bernat ;
Codony, Carles ;
Ferrer, Gerardo ;
Martinez, Carmen ;
Montserrat, Emili ;
Monzo, Mariano .
BLOOD, 2009, 114 (14) :2945-2951
[17]   Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression [J].
Nör, JE ;
Christensen, J ;
Mooney, DJ ;
Polverini, PJ .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (02) :375-384
[18]  
Rami-Porta R, 2009, ANN THORAC CARDIOVAS, V15, P4
[19]   Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells [J].
Salani, Barbara ;
Maffioli, Sara ;
Hamoudane, Meriem ;
Parodi, Alessia ;
Ravera, Silvia ;
Passalacqua, Mario ;
Alama, Angela ;
Nhiri, Mohamed ;
Cordera, Renzo ;
Maggi, Davide .
FASEB JOURNAL, 2012, 26 (02) :788-798
[20]   First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations [J].
Sequist, Lecia V. ;
Martins, Renato G. ;
Spigel, David ;
Grunberg, Steven M. ;
Spira, Alexander ;
Jaenne, Pasi A. ;
Joshi, Victoria A. ;
McCollum, David ;
Evans, Tracey L. ;
Muzikansky, Alona ;
Kuhlmann, Georgiana L. ;
Han, Moon ;
Goldberg, Jonathan S. ;
Settleman, Jeffrey ;
Iafrate, A. John ;
Engelman, Jeffrey A. ;
Haber, Daniel A. ;
Johnson, Bruce E. ;
Lynch, Thomas J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2442-2449